Hutchings, MartinRadford, JohnAnsell, Stephen M.Illés, ÁrpádSureda, AnnaConnors, Joseph M.Sýkorová, AliceShibayama, HirohikoAbramson, Jeremy S.Chua, Neil S.Friedberg, Jonathan W.Koren, JanSteward LaCasce, AnnMolina, LysianeEngley, GeraldFenton, KeenanJolin, HinaLiu, RachelGautam, AshishGallamini, Andrea2021-03-152021-03-152021-01-180278-0232https://hdl.handle.net/2445/175055Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON‐1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first‐line therapy after a median follow‐up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD‐treated versus ABVD‐treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high‐risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON‐1 shows a favorable benefit‐risk balance in high‐risk patients.11 p.application/pdfengcc by-nd-nc (c) Hutchings, Martin et al., 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/Malaltia de HodgkinAssaigs clínicsPronòstic mèdicHodgkin's diseaseClinical trialsPrognosisinfo:eu-repo/semantics/article7069562021-03-15info:eu-repo/semantics/openAccess33462822